Tuberculosis, a disease that primarily affects the lungs, is still a leading infectious killer estimated to have caused 1.3 million deaths in 2022. Three EPI members bring unique approaches to fighting TB.
A researcher at the UF Emerging Pathogens Institute partners with a tech company to study sterilization of samples received from Space.
Dr. Josephine Clark-Curtiss, whose career spanned half a century, worked tirelessly to help mitigate the spread of dangerous infectious diseases. After a valiant personal battle against ovarian cancer, she passed away on Nov. 6, 2023.
UF EPI member studies how the genetic makeup of a tuberculosis bacterial population changes during transmission.
A new study from University of Florida and Kansas State University researchers found that bison carry plant-associated fungi in their saliva, with the potential to spread fungi across the prairie.
A UF researcher with expertise in infectious bacteria offers commentary and perspective on extensively drug-resistant Shigella infections following a recent CDC warning.
Graduate student Amanda Ojeda won best research poster in the EPI Research Day 2023 trainee research poster competition. Her research focused on identifying the prevalence and the composition of Campylobacter species in infants in a rural area of eastern Ethiopia during their first year of life and potential reservoirs. The project was a team collaboration between Ojeda and collaborators at the University of Florida, Haramaya University, Ohio State University, Washington University in St. Louis and Massey University in New Zealand.
UF’s EPI is partnering with Gainesville-based tech company SurfPlasma, Inc. to test a new device’s ability to kill pathogens — even the celestial kinds.
New research by UF investigators on Salmonella infections in Florida highlights the influence of seasons, geography and age upon transmission patterns. The team also developed new AI-based methods for detecting outbreaks and linking cases to environmental or food sources.
Tuberculosis is an age-old respiratory scourge, with a new twist: growing resistance to multiple first- and second-line drugs. UF researchers and physicians report on using a novel treatment to slash treatment time — and cure — a patient with extensively drug-resistant TB.
